A study of the mechanisms of action of Fertiwell in vivo
AIM: To investigate the specific mechanisms of action of Fertiwell in a mouse model of D-galactose-induced aging of the reproductive system.
MATERIALS AND METHODS: C57BL/6J mice were randomized into four groups: intact mice (control group), a group of mice with artificial accelerated aging treated with D-galactose alone (Gal), D-galactose followed by Fertiwell (PP), and D-galactose followed by a combination of L-carnitine and acetyl-L-carnitine (LC). The artificial accelerated aging of reproductive system was induced by daily intraperitoneal administration of D-galactose at a dose of 100 mg/kg for 8 weeks. After the end of therapy in all groups, the characteristics of sperm, the level of serum testosterone, immunohistochemical parameters, and the expression of specific proteins were evaluated.
RESULTS: Fertiwell had a pronounced therapeutic effect on testicular tissues and spermatozoa, restored testosterone levels to normal values, and, in addition, was more effective protector against oxidative stress in the reproductive system compared to L-carnitine and acetyl-L-carnitine, which are widely used in male infertility. Fertiwell at a dose of 1 mg/kg allowed to significantly increase the number of motile spermatozoa to 67.4+/-3.1%, which was comparable to indicators in the intact group. The introduction of the Fertiwell positively affected the activity of mitochondria, which was also expressed in an increase in sperm motility. In addition, Fertiwell restored the intracellular level of ROS to the values of the control group and reduced the number of TUNEL+ cells (with fragmented DNA) to the level of intact control. Thus, Fertiwell, containing testis polypeptides, has a complex effect on reproductive function, leading to a change in gene expression, an increase in protein synthesis, the prevention of DNA damage in the testicular tissue, and an increase in mitochondrial activity in testicular tissue and spermatozoa of the vas deferens, which leads to the subsequent improvement of testicular function.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Urologiia (Moscow, Russia : 1999) - (2023), 1 vom: 02. März, Seite 60-70 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Khochenkova, Yu A [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 05.07.2023 Date Revised 05.07.2023 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM359028764 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359028764 | ||
| 003 | DE-627 | ||
| 005 | 20231226080007.0 | ||
| 007 | tu | ||
| 008 | 231226s2023 xx ||||| 00| ||rus c | ||
| 028 | 5 | 2 | |a pubmed24n1196.xml |
| 035 | |a (DE-627)NLM359028764 | ||
| 035 | |a (NLM)37401685 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Khochenkova, Yu A |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A study of the mechanisms of action of Fertiwell in vivo |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 05.07.2023 | ||
| 500 | |a Date Revised 05.07.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM: To investigate the specific mechanisms of action of Fertiwell in a mouse model of D-galactose-induced aging of the reproductive system | ||
| 520 | |a MATERIALS AND METHODS: C57BL/6J mice were randomized into four groups: intact mice (control group), a group of mice with artificial accelerated aging treated with D-galactose alone (Gal), D-galactose followed by Fertiwell (PP), and D-galactose followed by a combination of L-carnitine and acetyl-L-carnitine (LC). The artificial accelerated aging of reproductive system was induced by daily intraperitoneal administration of D-galactose at a dose of 100 mg/kg for 8 weeks. After the end of therapy in all groups, the characteristics of sperm, the level of serum testosterone, immunohistochemical parameters, and the expression of specific proteins were evaluated | ||
| 520 | |a RESULTS: Fertiwell had a pronounced therapeutic effect on testicular tissues and spermatozoa, restored testosterone levels to normal values, and, in addition, was more effective protector against oxidative stress in the reproductive system compared to L-carnitine and acetyl-L-carnitine, which are widely used in male infertility. Fertiwell at a dose of 1 mg/kg allowed to significantly increase the number of motile spermatozoa to 67.4+/-3.1%, which was comparable to indicators in the intact group. The introduction of the Fertiwell positively affected the activity of mitochondria, which was also expressed in an increase in sperm motility. In addition, Fertiwell restored the intracellular level of ROS to the values of the control group and reduced the number of TUNEL+ cells (with fragmented DNA) to the level of intact control. Thus, Fertiwell, containing testis polypeptides, has a complex effect on reproductive function, leading to a change in gene expression, an increase in protein synthesis, the prevention of DNA damage in the testicular tissue, and an increase in mitochondrial activity in testicular tissue and spermatozoa of the vas deferens, which leads to the subsequent improvement of testicular function | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Fertiwell | |
| 650 | 4 | |a antioxidant therapy | |
| 650 | 4 | |a male infertility | |
| 650 | 4 | |a oxidative stress | |
| 650 | 4 | |a regulatory peptides | |
| 650 | 7 | |a Acetylcarnitine |2 NLM | |
| 650 | 7 | |a 6DH1W9VH8Q |2 NLM | |
| 650 | 7 | |a Galactose |2 NLM | |
| 650 | 7 | |a X2RN3Q8DNE |2 NLM | |
| 650 | 7 | |a Carnitine |2 NLM | |
| 650 | 7 | |a S7UI8SM58A |2 NLM | |
| 650 | 7 | |a Testosterone |2 NLM | |
| 650 | 7 | |a 3XMK78S47O |2 NLM | |
| 700 | 1 | |a Machkova, Yu S |e verfasserin |4 aut | |
| 700 | 1 | |a Khochenkova, D A |e verfasserin |4 aut | |
| 700 | 1 | |a Sidorova, T A |e verfasserin |4 aut | |
| 700 | 1 | |a Safarova, E R |e verfasserin |4 aut | |
| 700 | 1 | |a Bastrikova, N A |e verfasserin |4 aut | |
| 700 | 1 | |a Korzhova, K V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Urologiia (Moscow, Russia : 1999) |d 1999 |g (2023), 1 vom: 02. März, Seite 60-70 |w (DE-627)NLM110630386 |x 1728-2985 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g number:1 |g day:02 |g month:03 |g pages:60-70 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |e 1 |b 02 |c 03 |h 60-70 | ||